DIATRIZOATE-60 Drug Patent Profile
✉ Email this page to a colleague
When do Diatrizoate-60 patents expire, and when can generic versions of Diatrizoate-60 launch?
Diatrizoate-60 is a drug marketed by Intl Medication and is included in one NDA.
The generic ingredient in DIATRIZOATE-60 is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diatrizoate-60
A generic version of DIATRIZOATE-60 was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DIATRIZOATE-60?
- What are the global sales for DIATRIZOATE-60?
- What is Average Wholesale Price for DIATRIZOATE-60?
Summary for DIATRIZOATE-60
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | DIATRIZOATE-60 at DailyMed |
Recent Clinical Trials for DIATRIZOATE-60
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | |
| General Electric | |
| Milton S. Hershey Medical Center | N/A |
US Patents and Regulatory Information for DIATRIZOATE-60
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intl Medication | DIATRIZOATE-60 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 088166-001 | Jun 17, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
